Rathbones Group PLC Nektar Therapeutics Transaction History

Rathbones Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $171,972 - $239,088	-10,200 Closed	0 $0
Q2 2018 Jul 16, 2018	SELL	$46.25 - $104.45 $245,125 - $553,585	-5,300 Reduced 34.19%	10,200 $498,000
Q1 2018 Apr 06, 2018	SELL	$57.4 - $108.44 $17,220 - $32,532	-300 Reduced 1.9%	15,500 $1.65 Million
Q4 2017 Jan 24, 2018	SELL	$23.02 - $60.5 $46,040 - $121,000	-2,000 Reduced 11.24%	15,800 $944,000
Q3 2017 Oct 24, 2017	BUY	$17.79 - $24.0 $316,662 - $427,200	17,800	17,800 $427,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

Stay updated on Rathbones Group PLC with notifications on news.